国邦医药集团股份有限公司 简式权益变动报告书 上市公司名称：国邦医药集团股份有限公司 股票上市地点：上海证券交易所 股票简称：国邦医药 股票代码：605507 信息披露义务人：潍坊仕琦汇股权投资合伙企业（有限合伙） 住所：山东省潍坊市滨海区观海路 00266 号滨海资本管理中心 5 号楼 102 室 签署日期：2025 年 8 月 20 日 国邦医药集团股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购管理办法》"）、《公开发行证 券的公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准 则 15 号》"）及其他相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 通讯地址：山东潍坊市滨海区香江西一街 02131 号 权益变动性质：股份减少（协议转让） 三、依据《证券法》《收购管理办法》《准则 15 号》的规定，本报告书已 全面披露信息披露义务人在国邦医药集团股份有限公司中拥有权益的股份变动 情况。 四、截至本报告书签署之日 ...

信息披露义务人：浙江省国有资本运营有限公司 注册地址：浙江省杭州市求是路8号公元大厦北楼25楼 权益变动性质：股份增加（协议受让） 上市公司名称: 国邦医药集团股份有限公司 国邦医药集团股份有限公司 简式权益变动报告书 签署日期：2025年8月20日 上市地点：上海证券交易所 股票简称：国邦医药 股票代码：605507 声 明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》 及相关法律法规编写本权益变动报告书（以下简称"本报告书"）。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程和内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号—权益变动报告书》的规定，本报告 书已全面披露信息披露义务人在国邦医药集团股份有限公司（以下简称"国邦医 药"）中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没 有通过任何其他方式增加或减少其在国邦医药中拥有 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-038 国邦医药集团股份有限公司 关于公司股东协议转让股份引入战略投资者暨权益 变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基于公司战略发展需要，引入看好公司价值和看好公司未来发展的战略 投资者，共同推动医药产业的创新发展，国邦医药集团股份有限公司（以下简称 "公司"、"目标公司"、"国邦医药"）持股 5%以上股东潍坊仕琦汇股权投资合 伙企业（有限合伙）（以下简称"仕琦汇" 、"转让方 1"）、潍坊洪德辉股权投资 合伙企业（有限合伙）（以下简称"洪德辉"、"转让方 2"）及绍兴世庆德企业管理 咨询合伙企业（有限合伙）（以下简称"世庆德"、"转让方 3"）于 2025 年 8 月 20 日与浙江省国有资本运营有限公司（以下简称"国有运营公司"、"受让方"）签署 了《股份转让协议》（以下简称"本协议"），仕琦汇、洪德辉及世庆德拟通过协 议转让的方式向国有运营公司转让其首次公开发行股票前持有的公司股份 38,306,303 ...

Core Viewpoint - Guobang Pharmaceutical (605507.SH) has signed a share transfer agreement with Zhejiang State-owned Capital Operation Co., Ltd. to transfer 38,306,303 shares, representing 6.85% of the total share capital, to support the company's strategic development in the pharmaceutical industry [1][2] Group 1 - The share transfer involves major shareholders, including Weifang Shiqihui Equity Investment Partnership, Weifang Hongdehui Equity Investment Partnership, and Shaoxing Shiqingde Enterprise Management Consulting Partnership, who will collectively hold 4.91% of the company's shares after the transfer [1] - The state-owned operation company aims to support the comprehensive development of the company in the pharmaceutical sector, focusing on areas such as industrial chain collaboration, new business cultivation, and capital operations [2] - Future cooperation will involve personnel exchanges and collaborative efforts in investment project evaluation, new technology validation, application scenarios, and think tank consulting, with specific details to be negotiated and formalized in subsequent agreements [2]

Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The company reported a strong performance in H1 2025, with revenue of 3.026 billion yuan (up 4.63% YoY) and a net profit of 456 million yuan (up 12.6% YoY) [1] - The animal health segment showed significant growth, contributing to the overall profitability, with revenue from this segment reaching 1.259 billion yuan (up 53.5% YoY) [1][2] - The company maintains a solid position in the pharmaceutical raw materials sector, while the animal health business benefits from economies of scale and reduced marginal costs [1][2] Summary by Sections Financial Performance - In H1 2025, the company achieved a gross margin of 26.85% (up 0.26 percentage points YoY) and a net margin of 15.0% (up 1.02 percentage points YoY) [1] - The revenue breakdown shows that the pharmaceutical segment accounted for approximately 60% of total revenue, while the animal health segment accounted for 42% [1] Business Segments - The company has a diverse portfolio in animal health products, with 16 registered raw materials in China, indicating strong competitive advantages [2] - The company’s key products in the animal health sector include Florfenicol, Oxytetracycline, and Enrofloxacin, which have established brand advantages [2] Future Outlook - The company is expected to continue focusing on its core pharmaceutical and animal health products while exploring new growth opportunities in specialty raw materials [3] - Revenue projections for 2025-2027 are 6.750 billion yuan, 7.811 billion yuan, and 8.861 billion yuan respectively, with corresponding net profits of 958 million yuan, 1.153 billion yuan, and 1.339 billion yuan [3][8]

证券代码：605507 证券简称：国邦医药 公告编号：2025-037 国邦医药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 8 月 18 日（星期一）下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 9 日（星期六）至 8 月 17 日（星期日）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@gbgcn.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 国邦医药集团股份有限公司（以下简称"公司"）已于 2025 年 7 月 30 日发布 公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年 度的经营成果、财务状况，公司计划于 ...

Core Insights - The report highlights the importance of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the raw material pharmaceutical sector is 661,200 yuan [1] Salary Distribution - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical with 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical with 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical with 1.57 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 60 and above account for 5% [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, and only 2% have a high school diploma [1] Salary Changes - Liu Qingke from Huangshan Capsule experienced the largest salary decrease at 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase at 100.58% [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Among the CFOs, those aged 40-50 represent the majority at 36%, while those aged 60 and above account for 5% [1] - The youngest CFO currently in office is 33 years old, from XinNuoWei, named Dai Long [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, while another 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total salary scale for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Salary Distribution - The average salary for CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan, with 44% earning below 500,000 yuan, 44% between 500,000 and 1 million yuan, and 12% above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2] CFO Age Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 50-60 account for 33%, and those aged 40 and below make up 26%. Only 5% of CFOs are over 60 years old [1] CFO Educational Background - The educational background of CFOs shows that 2% have a high school diploma, 12% have an associate degree, 65% hold a bachelor's degree, and 21% possess a master's degree. Notably, only one CFO has a high school education [1] Salary Changes - Among CFOs with over two years of tenure, Liu Qingke from Huangshan Capsule experienced the largest salary decrease of 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase of 100.58% [2]

Core Insights - The report highlights the significant role of company secretaries (董秘) as a bridge between investors and listed companies, emphasizing their importance in capital operations within the A-share market [1] Salary Overview - The total salary for A-share company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - In the raw material pharmaceutical sector, the average annual salary for company secretaries is 608,400 yuan [1] Demographics - The age distribution shows that 60% of company secretaries are between 30-50 years old, while 38% are over 50, and only 2% are 30 or younger [1] - Educational background indicates that over 50% of company secretaries hold a bachelor's degree, with 9% having an associate degree, 39% holding a master's degree [1] Salary Distribution in Raw Material Pharmaceutical Sector - Among company secretaries in the raw material pharmaceutical sector, 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn over 1 million yuan [1] Top Earners - The top five highest-paid company secretaries are from Guobang Pharmaceutical, Saifen Technology, Keyuan Pharmaceutical, Aorite, and Zhejiang Pharmaceutical, with salaries ranging from 1.0832 million to 1.9309 million yuan [2] - The lowest-paid company secretaries earn below 200,000 yuan, with their salaries ranging from 174,200 to 190,700 yuan [2]